丁丙诺啡治疗缺口与阿片类药物过量和医疗支出的关联
治疗缺口月份过量风险为治疗月份的2.89倍,支出增加196.41美元。维持剂量≤8 mg/d者在缺口月份过量风险更高。
要点
- 丁丙诺啡治疗缺口月份阿片类药物过量风险是治疗月份的2.89倍。
- 治疗缺口月份总医疗支出比治疗月份增加196.41美元。
- 维持剂量≤8 mg/d者在缺口月份过量风险为3.62倍,高于更高剂量者。
核心结论
- Medicare丁丙诺啡治疗患者在治疗月份的阿片类药物过量风险和医疗支出均低于治疗缺口月份。
主要发现
- 治疗缺口月份阿片类药物过量风险为治疗月份的2.89倍(95%CI 2.20-3.79)。
- 治疗缺口月份支出比治疗月份多196.41美元(95%CI 110.53-282.30)。
- 维持剂量>16 mg/d者在缺口月份过量风险HR为2.64(95%CI 1.80-3.87),>8 mg/d者为2.84(95%CI 2.13-3.78),≤8 mg/d者为3.62(95%CI 1.54-8.50)。
- 丁丙诺啡单药治疗在缺口月份与更高过量风险和更高支出相关。
关键数值与推荐
- 治疗缺口定义为一个月内连续超过15天未接受丁丙诺啡治疗。
- 主要结局为阿片类药物过量以及总支出、医疗支出和药物支出(患者自付与Medicare支出合计)。
临床怎么用
- 临床应关注丁丙诺啡治疗的连续性,减少治疗缺口以降低阿片类药物过量风险和医疗支出。
- 对维持剂量≤8 mg/d及使用丁丙诺啡单药治疗的患者,尤其需要监测治疗中断风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nonadherence to buprenorphine may increase patient risk of opioid overdose and increase health care spending. Quantifying the impacts of nonadherence can help inform clinician practice and policy. OBJECTIVE: To estimate the association between buprenorphine treatment gaps, opioid overdose, and health care spending. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal case-control study compared patient opioid overdose and health care spending in buprenorphine-treated months with treatment gap months. Individuals who were US Medicare fee-for-service beneficiaries diagnosed with opioid use disorder who received at least 1 two-week period of continuous buprenorphine treatment between 2010 and 2017 were included. Analysis took place between January 2010 and December 2017. INTERVENTIONS: A gap in buprenorphine treatment in a month lasting more than 15 consecutive days. MAIN OUTCOMES AND MEASURES: Opioid overdose and total, medical, and drug spending (combined patient out-of-pocket and Medicare spending). RESULTS: Of 34 505 Medicare beneficiaries (17 927 [520%] male; 16 578 [48.1%] female; mean [SD] age, 49.5 [12.7] years; 168 [0.5%] Asian; 2949 [8.5%] Black; 2089 [6.0%] Hispanic; 266 [0.8%] Native American; 28 525 [82.7%] White; 508 [1.5%] other race), 11 524 beneficiaries (33.4%) experienced 1 or more buprenorphine treatment gaps. Treatment gap beneficiaries, compared with nontreatment gap beneficiaries, were more likely to be younger, be male, have a disability, and be Medicaid dual-eligible while less likely to be White, close to a buprenorphine prescriber, and treated with buprenorphine monotherapy (ie, buprenorphine hydrochloride). Beneficiaries were 2.89 (95% CI, 2.20-3.79) times more likely to experience an opioid overdose during buprenorphine treatment gap months compared with treated months. During treatment gap months, spending was $196.41 (95% CI, $110.53-$282.30) more than in treated months. Patients who continued to take buprenorphine dosages of greater than 8 mg/d and 16 mg/d were 2.61 and 2.84 times more likely to overdose in a treatment gap month, respectively, while patients taking buprenorphine dosages of 8 mg/d or less were 3.62 times more likely to overdose in a treatment gap month (maintenance of >16 mg/d: hazard ratio (HR), 2.64 [95% CI, 1.80-3.87]; maintenance of >8 mg/d: HR, 2.84 [95% CI, 2.13-3.78]; maintenance of ≤8 mg/d: HR, 3.62 [95% CI, 1.54-8.50]). Buprenorphine monotherapy was associated with greater risk of overdose and higher spending during treatment gaps months than buprenorphine/naloxone. CONCLUSIONS AND RELEVANCE: Medicare patients treated with buprenorphine between 2010 and 2017 had a lower associated opioid overdose risk and spending during treatment months than treatment gap months.
引用
- Gibbons JB, McCullough JS, Zivin K, et al. Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder. JAMA Psychiatry. 2022. PMID: 36197659. doi:10.1001/jamapsychiatry.2022.3118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。